Black Diamond Therapeutics (BDTX) Change in Accured Expenses: 2018-2024
Historic Change in Accured Expenses for Black Diamond Therapeutics (BDTX) over the last 7 years, with Dec 2024 value amounting to -$756,000.
- Black Diamond Therapeutics' Change in Accured Expenses fell 156.92% to -$2.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $8.7 million, marking a year-over-year increase of 8.57%. This contributed to the annual value of -$756,000 for FY2024, which is 119.20% down from last year.
- Per Black Diamond Therapeutics' latest filing, its Change in Accured Expenses stood at -$756,000 for FY2024, which was down 119.20% from $3.9 million recorded in FY2023.
- Black Diamond Therapeutics' Change in Accured Expenses' 5-year high stood at $8.7 million during FY2021, with a 5-year trough of -$5.9 million in FY2022.
- For the 3-year period, Black Diamond Therapeutics' Change in Accured Expenses averaged around -$894,000, with its median value being -$756,000 (2024).
- Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 348.13% in 2020, then slumped by 167.29% in 2022.
- Black Diamond Therapeutics' Change in Accured Expenses (Yearly) stood at $8.0 million in 2020, then climbed by 8.57% to $8.7 million in 2021, then slumped by 167.29% to -$5.9 million in 2022, then skyrocketed by 167.16% to $3.9 million in 2023, then slumped by 119.20% to -$756,000 in 2024.